ENvue Medical, Inc. (FEED) Spending and interest coverage
- R&D / revenue · 12 months: Value 63.29%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 63.29% | Research and development expense / revenue. Period ending 2026-06-30. $1.22M ÷ $1.93M × 100 ≈ 63.29% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.22M USD | Research and Development Expense |
| Revenue | 1.93M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -26.25M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.22M | $1.93M | (m) | $-26.25M | (m) | 63.29% | (m) | (m) | (m) |
| 2026-03-31 | $1.70M | $2.18M | (m) | $-24.75M | (m) | 77.95% | (m) | (m) | (m) |
| 2025-12-31 | $1.76M | $2.55M | (m) | $-22.89M | (m) | 69.02% | (m) | (m) | (m) |
| 2025-09-30 | $2.08M | $2.69M | (m) | $-9.45M | (m) | 77.28% | (m) | (m) | (m) |
| 2025-06-30 | $2.10M | $2.34M | (m) | $-8.17M | $264.00K | 89.91% | (m) | -30.94× | Reported |
| 2025-03-31 | $1.32M | $2.66M | (m) | $-4.87M | $154.00K | 49.51% | (m) | -31.60× | Reported |
| 2024-12-31 | $909.00K | $2.56M | $356.00K | $-3.58M | $135.00K | 35.54% | 13.92% | -26.53× | Reported |
| 2024-09-30 | $619.00K | $3.29M | $289.00K | $-2.91M | $134.00K | 18.81% | 8.78% | -21.75× | Reported |
| 2024-06-30 | $403.00K | $3.37M | $267.00K | $-2.61M | $136.00K | 11.95% | 7.92% | -19.22× | Reported |
| 2024-03-31 | $251.00K | $2.85M | $333.00K | $-2.95M | $135.00K | 8.81% | 11.68% | -21.84× | Reported |
| 2023-12-31 | $185.00K | $2.28M | $293.00K | $-3.44M | $135.00K | 8.10% | 12.83% | -25.45× | Reported |
| 2023-09-30 | $230.00K | $1.00M | $236.00K | $-4.44M | (m) | 22.91% | 23.51% | (m) | (m) |
| 2023-06-30 | $246.00K | $643.00K | $181.00K | $-4.70M | (m) | 38.26% | 28.15% | (m) | (m) |
| 2023-03-31 | $272.00K | $834.00K | $335.00K | $-4.96M | (m) | 32.61% | 40.17% | (m) | (m) |
| 2022-12-31 | $283.00K | $752.00K | $354.00K | $-5.01M | $347.00K | 37.63% | 47.07% | -14.44× | Reported |
| 2022-09-30 | $291.00K | $1.63M | $555.00K | $-5.81M | (m) | 17.86% | 34.07% | (m) | (m) |
| 2022-06-30 | $292.00K | $2.03M | $480.00K | $-5.76M | (m) | 14.38% | 23.63% | (m) | (m) |
| 2022-03-31 | $295.00K | $1.86M | $359.00K | $-5.48M | (m) | 15.83% | 19.26% | (m) | (m) |
| 2021-12-31 | $293.00K | $1.70M | $382.00K | $-5.68M | (m) | 17.29% | 22.54% | (m) | (m) |
| 2021-09-30 | $218.00K | $1.01M | $164.00K | $-4.71M | (m) | 21.58% | 16.24% | (m) | (m) |
| 2021-06-30 | $236.00K | $661.00K | $441.00K | $-4.65M | (m) | 35.70% | 66.72% | (m) | (m) |
| 2021-03-31 | $188.00K | $612.00K | $414.00K | $-5.13M | (m) | 30.72% | 67.65% | (m) | (m) |
| 2020-12-31 | $171.00K | $623.00K | $376.00K | $-4.72M | $147.00K | 27.45% | 60.35% | -32.10× | Reported |
| 2020-09-30 | $264.00K | $620.00K | $525.00K | $-4.42M | $128.00K | 42.58% | 84.68% | -34.52× | Reported |
| 2020-06-30 | $275.00K | $571.00K | $452.00K | $-4.41M | (m) | 48.16% | 79.16% | (m) | (m) |
| 2020-03-31 | $409.00K | $565.00K | $491.00K | $-3.83M | (m) | 72.39% | 86.90% | (m) | (m) |
| 2019-12-31 | $514.00K | $530.00K | $1.75M | $-5.15M | $15.00K | 96.98% | 331.13% | -343.40× | Reported |
| 2019-09-30 | $587.00K | $497.00K | $1.78M | $-5.28M | (m) | 118.11% | 357.95% | (m) | (m) |
| 2019-06-30 | $630.00K | $451.00K | $2.17M | $-5.81M | (m) | 139.69% | 480.49% | (m) | (m) |
| 2019-03-31 | $630.00K | $320.00K | $2.12M | $-5.74M | (m) | 196.88% | 660.94% | (m) | (m) |
| 2018-12-31 | $614.00K | $318.00K | $889.00K | $-4.30M | (m) | 193.08% | 279.56% | (m) | (m) |
| 2018-09-30 | $627.00K | $334.00K | $783.00K | $-3.96M | (m) | 187.72% | 234.43% | (m) | (m) |
| 2018-06-30 | $665.00K | $344.00K | $432.00K | $-3.24M | (m) | 193.31% | 125.58% | (m) | (m) |
| 2018-03-31 | $679.00K | $264.00K | $558.00K | $-3.08M | (m) | 257.20% | 211.36% | (m) | (m) |
| 2017-12-31 | $693.00K | $239.00K | $800.00K | $-3.09M | (m) | 289.96% | 334.73% | (m) | (m) |
| 2017-09-30 | $611.00K | $218.00K | $907.00K | $-2.92M | (m) | 280.28% | 416.06% | (m) | (m) |
| 2017-06-30 | $611.00K | $214.00K | $923.00K | $-2.85M | (m) | 285.51% | 431.31% | (m) | (m) |
| 2017-03-31 | $620.00K | $224.00K | $794.00K | $-2.64M | (m) | 276.79% | 354.46% | (m) | (m) |
| 2016-12-31 | $584.00K | $229.00K | $508.00K | $-2.32M | (m) | 255.02% | 221.83% | (m) | (m) |
| 2016-09-30 | $549.00K | $219.00K | $351.00K | $-1.94M | (m) | 250.68% | 160.27% | (m) | (m) |
| 2016-06-30 | $476.00K | $198.00K | $260.00K | $-1.73M | (m) | 240.40% | 131.31% | (m) | (m) |
| 2016-03-31 | $418.00K | $175.00K | $275.00K | $-1.59M | (m) | 238.86% | 157.14% | (m) | (m) |
| 2015-12-31 | $399.00K | $147.00K | $220.00K | $-1.42M | (m) | 271.43% | 149.66% | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $431.00K | $203.00K | $24.00K | $-1.21M | (m) | 212.32% | 11.82% | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bone Biologics Corp (BBLG) | United States | $0.001B | |
| Lifeward Ltd. (LFWD) | $0.021B | ||
| LogicMark, Inc. (LGMK) | United States | $0.000B | |
| MILESTONE SCIENTIFIC INC. (MLSS) | United States | $0.036B | -6.85 |
| ALPHA PRO TECH LTD (APT) | $0.052B | 13.63 | |
| Envoy Medical, Inc. (COCH) | United States | $0.056B | |
| MYOMO, INC. (MYO) | United States | $0.065B | -2.85 |
| Safe Pro Group Inc. (SPAI) | United States | $0.090B | |
| LAKELAND INDUSTRIES INC (LAKE) | United States | $0.104B | -4.21 |
| NutriBand Inc. (NTRB) | United States | $0.109B |